Ruxolitinib
Medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Ruxolitinib?
Summarize this article for a 10 years old
Ruxolitinib, sold under the brand name Jakafi among others, is a medication used for the treatment of intermediate or high-risk myelofibrosis,[5] a type of myeloproliferative neoplasm that affects the bone marrow;[10][11] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea;[5][12] and steroid-refractory acute graft-versus-host disease.[5] Ruxolitinib is a Janus kinase inhibitor.[5] It was developed and marketed by Incyte Corp in the US under the brand name Jakafi,[5] and by Novartis elsewhere in the world, under the brand name Jakavi.[13]
 | |
| Clinical data | |
|---|---|
| Trade names | Jakafi, Jakavi, Opzelura |
| Other names | INCB018424, INC424 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a612006 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, topical |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 95%[9] |
| Protein binding | 97%[9] |
| Metabolism | Liver (mainly CYP3A4-mediated)[9] |
| Elimination half-life | 2.8-3 hours[9] |
| Excretion | Urine (74%), faeces (22%)[9] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H18N6 |
| Molar mass | 306.373 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
It was approved for medical use in the United States in 2011,[14] and in the European Union in 2012.[7] Ruxolitinib is the first FDA-approved pharmacologic treatment to address repigmentation in vitiligo patients.[15]